Smith J W, Bartlett M S, Queener S F, Durkin M M, Jay M A, Hull M T, Klein R S, Marr J J
Department of Pathology, Indiana University School of Medicine, Indianapolis.
Diagn Microbiol Infect Dis. 1987 Jun;7(2):113-8. doi: 10.1016/0732-8893(87)90028-9.
An inosine analog, 9-deazainosine, has previously been demonstrated to inhibit Pneumocystis carinii in culture with WI-38 cells. The present study shows that it is also effective against Pneumocystis carinii in immunosuppressed Sprague-Dawley rats with Pneumocystis carinii pneumonia. After 8 wk of immunosuppression, rats that developed severe Pneumocystis carinii pneumonia were treated with either 9-deazainosine or served as controls. After 15 days of therapy, animals were sacrificed and severity of infection determined by morphologic examination of lungs for numbers of Pneumocystis carinii. Treated animals had greatly reduced numbers of Pneumocystis carinii trophozoites and cysts, compared with controls. This drug shows promise for therapy of Pneumocystis carinii pneumonia and should be studied further.
一种肌苷类似物，9-去氮肌苷，先前已被证明在体外培养中能抑制WI-38细胞中的卡氏肺孢子虫。本研究表明，它对患有卡氏肺孢子虫肺炎的免疫抑制斯普拉格-道利大鼠中的卡氏肺孢子虫也有效。在免疫抑制8周后，对发生严重卡氏肺孢子虫肺炎的大鼠用9-去氮肌苷治疗或作为对照。治疗15天后，处死动物，通过对肺进行形态学检查以确定卡氏肺孢子虫数量来判断感染的严重程度。与对照组相比，治疗组动物的卡氏肺孢子虫滋养体和包囊数量大大减少。这种药物有望用于治疗卡氏肺孢子虫肺炎，应进一步研究。
